Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
6,786
archived clinical trials in
Dermatology

Assessing the Impact of Pioglitazone on Skin Barrier Function in Atopic Dermatitis Patients
Assessing the Impact of Pioglitazone on Skin Barrier Function in Atopic Dermatitis Patients
Status: Enrolling
Updated:  9/26/2012
Univ of Rochester Medical Center
mi
from
Rochester, NY
Assessing the Impact of Pioglitazone on Skin Barrier Function in Atopic Dermatitis Patients
Assessing the Impact of Pioglitazone on Skin Barrier Function in Atopic Dermatitis Patients
Status: Enrolling
Updated: 9/26/2012
Univ of Rochester Medical Center
mi
from
Rochester, NY
Click here to add this to my saved trials
Macitentan for the Treatment of Digital Ulcers in Systemic Sclerosis Patients
Propective, Randomized, Placebo-controlled, Double-blind, Multicenter, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Macitentan in Patients With Ischemic Digital Ulcers Associated With Systemic Sclerosis
Status: Enrolling
Updated:  9/27/2012
University of Arizona Arthritis Center
mi
from
Tucson, AZ
Macitentan for the Treatment of Digital Ulcers in Systemic Sclerosis Patients
Propective, Randomized, Placebo-controlled, Double-blind, Multicenter, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Macitentan in Patients With Ischemic Digital Ulcers Associated With Systemic Sclerosis
Status: Enrolling
Updated: 9/27/2012
University of Arizona Arthritis Center
mi
from
Tucson, AZ
Click here to add this to my saved trials
Macitentan for the Treatment of Digital Ulcers in Systemic Sclerosis Patients
Propective, Randomized, Placebo-controlled, Double-blind, Multicenter, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Macitentan in Patients With Ischemic Digital Ulcers Associated With Systemic Sclerosis
Status: Enrolling
Updated:  9/27/2012
UCLA Medical School - Rheumatology Division Rehabilitation Center
mi
from
Los Angeles, CA
Macitentan for the Treatment of Digital Ulcers in Systemic Sclerosis Patients
Propective, Randomized, Placebo-controlled, Double-blind, Multicenter, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Macitentan in Patients With Ischemic Digital Ulcers Associated With Systemic Sclerosis
Status: Enrolling
Updated: 9/27/2012
UCLA Medical School - Rheumatology Division Rehabilitation Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Macitentan for the Treatment of Digital Ulcers in Systemic Sclerosis Patients
Propective, Randomized, Placebo-controlled, Double-blind, Multicenter, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Macitentan in Patients With Ischemic Digital Ulcers Associated With Systemic Sclerosis
Status: Enrolling
Updated:  9/27/2012
Arthritis and Rheumatic Disease Specialties
mi
from
Aventura, FL
Macitentan for the Treatment of Digital Ulcers in Systemic Sclerosis Patients
Propective, Randomized, Placebo-controlled, Double-blind, Multicenter, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Macitentan in Patients With Ischemic Digital Ulcers Associated With Systemic Sclerosis
Status: Enrolling
Updated: 9/27/2012
Arthritis and Rheumatic Disease Specialties
mi
from
Aventura, FL
Click here to add this to my saved trials
Macitentan for the Treatment of Digital Ulcers in Systemic Sclerosis Patients
Propective, Randomized, Placebo-controlled, Double-blind, Multicenter, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Macitentan in Patients With Ischemic Digital Ulcers Associated With Systemic Sclerosis
Status: Enrolling
Updated:  9/27/2012
Sarasota Arthritis Research Center
mi
from
Sarasota, FL
Macitentan for the Treatment of Digital Ulcers in Systemic Sclerosis Patients
Propective, Randomized, Placebo-controlled, Double-blind, Multicenter, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Macitentan in Patients With Ischemic Digital Ulcers Associated With Systemic Sclerosis
Status: Enrolling
Updated: 9/27/2012
Sarasota Arthritis Research Center
mi
from
Sarasota, FL
Click here to add this to my saved trials
Macitentan for the Treatment of Digital Ulcers in Systemic Sclerosis Patients
Propective, Randomized, Placebo-controlled, Double-blind, Multicenter, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Macitentan in Patients With Ischemic Digital Ulcers Associated With Systemic Sclerosis
Status: Enrolling
Updated:  9/27/2012
Ochsner Medical Center
mi
from
New Orleans, LA
Macitentan for the Treatment of Digital Ulcers in Systemic Sclerosis Patients
Propective, Randomized, Placebo-controlled, Double-blind, Multicenter, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Macitentan in Patients With Ischemic Digital Ulcers Associated With Systemic Sclerosis
Status: Enrolling
Updated: 9/27/2012
Ochsner Medical Center
mi
from
New Orleans, LA
Click here to add this to my saved trials
Macitentan for the Treatment of Digital Ulcers in Systemic Sclerosis Patients
Propective, Randomized, Placebo-controlled, Double-blind, Multicenter, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Macitentan in Patients With Ischemic Digital Ulcers Associated With Systemic Sclerosis
Status: Enrolling
Updated:  9/27/2012
The Johns Hopkins University School of Medicine
mi
from
Baltimore, MD
Macitentan for the Treatment of Digital Ulcers in Systemic Sclerosis Patients
Propective, Randomized, Placebo-controlled, Double-blind, Multicenter, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Macitentan in Patients With Ischemic Digital Ulcers Associated With Systemic Sclerosis
Status: Enrolling
Updated: 9/27/2012
The Johns Hopkins University School of Medicine
mi
from
Baltimore, MD
Click here to add this to my saved trials
Macitentan for the Treatment of Digital Ulcers in Systemic Sclerosis Patients
Propective, Randomized, Placebo-controlled, Double-blind, Multicenter, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Macitentan in Patients With Ischemic Digital Ulcers Associated With Systemic Sclerosis
Status: Enrolling
Updated:  9/27/2012
University of Michigan-Scleroderma Program
mi
from
Ann Arbor, MI
Macitentan for the Treatment of Digital Ulcers in Systemic Sclerosis Patients
Propective, Randomized, Placebo-controlled, Double-blind, Multicenter, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Macitentan in Patients With Ischemic Digital Ulcers Associated With Systemic Sclerosis
Status: Enrolling
Updated: 9/27/2012
University of Michigan-Scleroderma Program
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Macitentan for the Treatment of Digital Ulcers in Systemic Sclerosis Patients
Propective, Randomized, Placebo-controlled, Double-blind, Multicenter, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Macitentan in Patients With Ischemic Digital Ulcers Associated With Systemic Sclerosis
Status: Enrolling
Updated:  9/27/2012
Michigan State University
mi
from
East Lansing, MI
Macitentan for the Treatment of Digital Ulcers in Systemic Sclerosis Patients
Propective, Randomized, Placebo-controlled, Double-blind, Multicenter, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Macitentan in Patients With Ischemic Digital Ulcers Associated With Systemic Sclerosis
Status: Enrolling
Updated: 9/27/2012
Michigan State University
mi
from
East Lansing, MI
Click here to add this to my saved trials
Macitentan for the Treatment of Digital Ulcers in Systemic Sclerosis Patients
Propective, Randomized, Placebo-controlled, Double-blind, Multicenter, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Macitentan in Patients With Ischemic Digital Ulcers Associated With Systemic Sclerosis
Status: Enrolling
Updated:  9/27/2012
University of Medicine & Dentistry of New Jersey, UMDNJ Scleroderma Program
mi
from
New Brunswick, NJ
Macitentan for the Treatment of Digital Ulcers in Systemic Sclerosis Patients
Propective, Randomized, Placebo-controlled, Double-blind, Multicenter, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Macitentan in Patients With Ischemic Digital Ulcers Associated With Systemic Sclerosis
Status: Enrolling
Updated: 9/27/2012
University of Medicine & Dentistry of New Jersey, UMDNJ Scleroderma Program
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
Macitentan for the Treatment of Digital Ulcers in Systemic Sclerosis Patients
Propective, Randomized, Placebo-controlled, Double-blind, Multicenter, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Macitentan in Patients With Ischemic Digital Ulcers Associated With Systemic Sclerosis
Status: Enrolling
Updated:  9/27/2012
Center for Rheumatology
mi
from
Albany, NY
Macitentan for the Treatment of Digital Ulcers in Systemic Sclerosis Patients
Propective, Randomized, Placebo-controlled, Double-blind, Multicenter, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Macitentan in Patients With Ischemic Digital Ulcers Associated With Systemic Sclerosis
Status: Enrolling
Updated: 9/27/2012
Center for Rheumatology
mi
from
Albany, NY
Click here to add this to my saved trials
Macitentan for the Treatment of Digital Ulcers in Systemic Sclerosis Patients
Propective, Randomized, Placebo-controlled, Double-blind, Multicenter, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Macitentan in Patients With Ischemic Digital Ulcers Associated With Systemic Sclerosis
Status: Enrolling
Updated:  9/27/2012
Shanahan Rheumatology and Immunotherapy, PLLC
mi
from
Raleigh, NC
Macitentan for the Treatment of Digital Ulcers in Systemic Sclerosis Patients
Propective, Randomized, Placebo-controlled, Double-blind, Multicenter, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Macitentan in Patients With Ischemic Digital Ulcers Associated With Systemic Sclerosis
Status: Enrolling
Updated: 9/27/2012
Shanahan Rheumatology and Immunotherapy, PLLC
mi
from
Raleigh, NC
Click here to add this to my saved trials
Macitentan for the Treatment of Digital Ulcers in Systemic Sclerosis Patients
Propective, Randomized, Placebo-controlled, Double-blind, Multicenter, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Macitentan in Patients With Ischemic Digital Ulcers Associated With Systemic Sclerosis
Status: Enrolling
Updated:  9/27/2012
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Macitentan for the Treatment of Digital Ulcers in Systemic Sclerosis Patients
Propective, Randomized, Placebo-controlled, Double-blind, Multicenter, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Macitentan in Patients With Ischemic Digital Ulcers Associated With Systemic Sclerosis
Status: Enrolling
Updated: 9/27/2012
Cleveland Clinic Foundation
mi
from
Cleveland, OH
Click here to add this to my saved trials
Macitentan for the Treatment of Digital Ulcers in Systemic Sclerosis Patients
Propective, Randomized, Placebo-controlled, Double-blind, Multicenter, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Macitentan in Patients With Ischemic Digital Ulcers Associated With Systemic Sclerosis
Status: Enrolling
Updated:  9/27/2012
Altoona Center for Clinical Research
mi
from
, PA
Macitentan for the Treatment of Digital Ulcers in Systemic Sclerosis Patients
Propective, Randomized, Placebo-controlled, Double-blind, Multicenter, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Macitentan in Patients With Ischemic Digital Ulcers Associated With Systemic Sclerosis
Status: Enrolling
Updated: 9/27/2012
Altoona Center for Clinical Research
mi
from
, PA
Click here to add this to my saved trials
Macitentan for the Treatment of Digital Ulcers in Systemic Sclerosis Patients
Propective, Randomized, Placebo-controlled, Double-blind, Multicenter, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Macitentan in Patients With Ischemic Digital Ulcers Associated With Systemic Sclerosis
Status: Enrolling
Updated:  9/27/2012
University of Pittsburgh Department of Rheumatology
mi
from
Pittsburgh, PA
Macitentan for the Treatment of Digital Ulcers in Systemic Sclerosis Patients
Propective, Randomized, Placebo-controlled, Double-blind, Multicenter, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Macitentan in Patients With Ischemic Digital Ulcers Associated With Systemic Sclerosis
Status: Enrolling
Updated: 9/27/2012
University of Pittsburgh Department of Rheumatology
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Macitentan for the Treatment of Digital Ulcers in Systemic Sclerosis Patients
Propective, Randomized, Placebo-controlled, Double-blind, Multicenter, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Macitentan in Patients With Ischemic Digital Ulcers Associated With Systemic Sclerosis
Status: Enrolling
Updated:  9/27/2012
Medical University of South Carolina
mi
from
Charleston, SC
Macitentan for the Treatment of Digital Ulcers in Systemic Sclerosis Patients
Propective, Randomized, Placebo-controlled, Double-blind, Multicenter, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Macitentan in Patients With Ischemic Digital Ulcers Associated With Systemic Sclerosis
Status: Enrolling
Updated: 9/27/2012
Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials
A Pilot Study to Investigate Filiation Between Primary and Secondary Lesions in Acne Patients
A Pilot Study to Investigate Filiation Between Primary and Secondary Lesions in Acne Patients
Status: Enrolling
Updated:  10/4/2012
Galderma Investigational site
mi
from
Baltimore, MD
A Pilot Study to Investigate Filiation Between Primary and Secondary Lesions in Acne Patients
A Pilot Study to Investigate Filiation Between Primary and Secondary Lesions in Acne Patients
Status: Enrolling
Updated: 10/4/2012
Galderma Investigational site
mi
from
Baltimore, MD
Click here to add this to my saved trials
Safety and Efficacy Study in Subjects With Seborrheic Dermatitis
A Parallel-group, Vehicle-controlled, Randomized, Double-blind Study of the Efficacy and Safety of Product 49778 and Product 10156 in Subjects With Seborrheic Dermatitis
Status: Enrolling
Updated:  10/7/2012
Clinical Research Facility
mi
from
Santa Clara, CA
Safety and Efficacy Study in Subjects With Seborrheic Dermatitis
A Parallel-group, Vehicle-controlled, Randomized, Double-blind Study of the Efficacy and Safety of Product 49778 and Product 10156 in Subjects With Seborrheic Dermatitis
Status: Enrolling
Updated: 10/7/2012
Clinical Research Facility
mi
from
Santa Clara, CA
Click here to add this to my saved trials
Safety and Efficacy Study in Subjects With Seborrheic Dermatitis
A Parallel-group, Vehicle-controlled, Randomized, Double-blind Study of the Efficacy and Safety of Product 49778 and Product 10156 in Subjects With Seborrheic Dermatitis
Status: Enrolling
Updated:  10/7/2012
Clinical Research Facility
mi
from
Bridgeport, CT
Safety and Efficacy Study in Subjects With Seborrheic Dermatitis
A Parallel-group, Vehicle-controlled, Randomized, Double-blind Study of the Efficacy and Safety of Product 49778 and Product 10156 in Subjects With Seborrheic Dermatitis
Status: Enrolling
Updated: 10/7/2012
Clinical Research Facility
mi
from
Bridgeport, CT
Click here to add this to my saved trials
Safety and Efficacy Study in Subjects With Seborrheic Dermatitis
A Parallel-group, Vehicle-controlled, Randomized, Double-blind Study of the Efficacy and Safety of Product 49778 and Product 10156 in Subjects With Seborrheic Dermatitis
Status: Enrolling
Updated:  10/7/2012
Clinical Research Facility
mi
from
Daytona Beach, FL
Safety and Efficacy Study in Subjects With Seborrheic Dermatitis
A Parallel-group, Vehicle-controlled, Randomized, Double-blind Study of the Efficacy and Safety of Product 49778 and Product 10156 in Subjects With Seborrheic Dermatitis
Status: Enrolling
Updated: 10/7/2012
Clinical Research Facility
mi
from
Daytona Beach, FL
Click here to add this to my saved trials
Safety and Efficacy Study in Subjects With Seborrheic Dermatitis
A Parallel-group, Vehicle-controlled, Randomized, Double-blind Study of the Efficacy and Safety of Product 49778 and Product 10156 in Subjects With Seborrheic Dermatitis
Status: Enrolling
Updated:  10/7/2012
Clinical Research Facility
mi
from
Decatur, GA
Safety and Efficacy Study in Subjects With Seborrheic Dermatitis
A Parallel-group, Vehicle-controlled, Randomized, Double-blind Study of the Efficacy and Safety of Product 49778 and Product 10156 in Subjects With Seborrheic Dermatitis
Status: Enrolling
Updated: 10/7/2012
Clinical Research Facility
mi
from
Decatur, GA
Click here to add this to my saved trials
Safety and Efficacy Study in Subjects With Seborrheic Dermatitis
A Parallel-group, Vehicle-controlled, Randomized, Double-blind Study of the Efficacy and Safety of Product 49778 and Product 10156 in Subjects With Seborrheic Dermatitis
Status: Enrolling
Updated:  10/7/2012
Clinical Research Facility
mi
from
Indianapolis, IN
Safety and Efficacy Study in Subjects With Seborrheic Dermatitis
A Parallel-group, Vehicle-controlled, Randomized, Double-blind Study of the Efficacy and Safety of Product 49778 and Product 10156 in Subjects With Seborrheic Dermatitis
Status: Enrolling
Updated: 10/7/2012
Clinical Research Facility
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Safety and Efficacy Study in Subjects With Seborrheic Dermatitis
A Parallel-group, Vehicle-controlled, Randomized, Double-blind Study of the Efficacy and Safety of Product 49778 and Product 10156 in Subjects With Seborrheic Dermatitis
Status: Enrolling
Updated:  10/7/2012
Clinical Research Facility
mi
from
Ann Arbor, MI
Safety and Efficacy Study in Subjects With Seborrheic Dermatitis
A Parallel-group, Vehicle-controlled, Randomized, Double-blind Study of the Efficacy and Safety of Product 49778 and Product 10156 in Subjects With Seborrheic Dermatitis
Status: Enrolling
Updated: 10/7/2012
Clinical Research Facility
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Safety and Efficacy Study in Subjects With Seborrheic Dermatitis
A Parallel-group, Vehicle-controlled, Randomized, Double-blind Study of the Efficacy and Safety of Product 49778 and Product 10156 in Subjects With Seborrheic Dermatitis
Status: Enrolling
Updated:  10/7/2012
Clinical Research Facility
mi
from
Rochester, MN
Safety and Efficacy Study in Subjects With Seborrheic Dermatitis
A Parallel-group, Vehicle-controlled, Randomized, Double-blind Study of the Efficacy and Safety of Product 49778 and Product 10156 in Subjects With Seborrheic Dermatitis
Status: Enrolling
Updated: 10/7/2012
Clinical Research Facility
mi
from
Rochester, MN
Click here to add this to my saved trials
Safety and Efficacy Study in Subjects With Seborrheic Dermatitis
A Parallel-group, Vehicle-controlled, Randomized, Double-blind Study of the Efficacy and Safety of Product 49778 and Product 10156 in Subjects With Seborrheic Dermatitis
Status: Enrolling
Updated:  10/7/2012
Clinical Research Facility
mi
from
Newark, NJ
Safety and Efficacy Study in Subjects With Seborrheic Dermatitis
A Parallel-group, Vehicle-controlled, Randomized, Double-blind Study of the Efficacy and Safety of Product 49778 and Product 10156 in Subjects With Seborrheic Dermatitis
Status: Enrolling
Updated: 10/7/2012
Clinical Research Facility
mi
from
Newark, NJ
Click here to add this to my saved trials
Safety and Efficacy Study in Subjects With Seborrheic Dermatitis
A Parallel-group, Vehicle-controlled, Randomized, Double-blind Study of the Efficacy and Safety of Product 49778 and Product 10156 in Subjects With Seborrheic Dermatitis
Status: Enrolling
Updated:  10/7/2012
Clinical Research Facility
mi
from
New York, NY
Safety and Efficacy Study in Subjects With Seborrheic Dermatitis
A Parallel-group, Vehicle-controlled, Randomized, Double-blind Study of the Efficacy and Safety of Product 49778 and Product 10156 in Subjects With Seborrheic Dermatitis
Status: Enrolling
Updated: 10/7/2012
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
Safety and Efficacy Study in Subjects With Seborrheic Dermatitis
A Parallel-group, Vehicle-controlled, Randomized, Double-blind Study of the Efficacy and Safety of Product 49778 and Product 10156 in Subjects With Seborrheic Dermatitis
Status: Enrolling
Updated:  10/7/2012
Clinical Research Facility
mi
from
Ashville, NC
Safety and Efficacy Study in Subjects With Seborrheic Dermatitis
A Parallel-group, Vehicle-controlled, Randomized, Double-blind Study of the Efficacy and Safety of Product 49778 and Product 10156 in Subjects With Seborrheic Dermatitis
Status: Enrolling
Updated: 10/7/2012
Clinical Research Facility
mi
from
Ashville, NC
Click here to add this to my saved trials
Safety and Efficacy Study in Subjects With Seborrheic Dermatitis
A Parallel-group, Vehicle-controlled, Randomized, Double-blind Study of the Efficacy and Safety of Product 49778 and Product 10156 in Subjects With Seborrheic Dermatitis
Status: Enrolling
Updated:  10/7/2012
Clinical Research Facility
mi
from
Portland, OR
Safety and Efficacy Study in Subjects With Seborrheic Dermatitis
A Parallel-group, Vehicle-controlled, Randomized, Double-blind Study of the Efficacy and Safety of Product 49778 and Product 10156 in Subjects With Seborrheic Dermatitis
Status: Enrolling
Updated: 10/7/2012
Clinical Research Facility
mi
from
Portland, OR
Click here to add this to my saved trials
Safety and Efficacy Study in Subjects With Seborrheic Dermatitis
A Parallel-group, Vehicle-controlled, Randomized, Double-blind Study of the Efficacy and Safety of Product 49778 and Product 10156 in Subjects With Seborrheic Dermatitis
Status: Enrolling
Updated:  10/7/2012
Clinical Research Facility
mi
from
Philadelphia, PA
Safety and Efficacy Study in Subjects With Seborrheic Dermatitis
A Parallel-group, Vehicle-controlled, Randomized, Double-blind Study of the Efficacy and Safety of Product 49778 and Product 10156 in Subjects With Seborrheic Dermatitis
Status: Enrolling
Updated: 10/7/2012
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Safety and Efficacy Study in Subjects With Seborrheic Dermatitis
A Parallel-group, Vehicle-controlled, Randomized, Double-blind Study of the Efficacy and Safety of Product 49778 and Product 10156 in Subjects With Seborrheic Dermatitis
Status: Enrolling
Updated:  10/7/2012
Clinical Research Facility
mi
from
Dallas, TX
Safety and Efficacy Study in Subjects With Seborrheic Dermatitis
A Parallel-group, Vehicle-controlled, Randomized, Double-blind Study of the Efficacy and Safety of Product 49778 and Product 10156 in Subjects With Seborrheic Dermatitis
Status: Enrolling
Updated: 10/7/2012
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
Safety and Efficacy Study in Subjects With Seborrheic Dermatitis
A Parallel-group, Vehicle-controlled, Randomized, Double-blind Study of the Efficacy and Safety of Product 49778 and Product 10156 in Subjects With Seborrheic Dermatitis
Status: Enrolling
Updated:  10/7/2012
Clinical Research Facility
mi
from
Salt Lake City, UT
Safety and Efficacy Study in Subjects With Seborrheic Dermatitis
A Parallel-group, Vehicle-controlled, Randomized, Double-blind Study of the Efficacy and Safety of Product 49778 and Product 10156 in Subjects With Seborrheic Dermatitis
Status: Enrolling
Updated: 10/7/2012
Clinical Research Facility
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Anakinra as a Treatment for Hydradenitis Suppurativa
An Open Label Non-randomized Study Assessing the Efficacy and Tolerability of Fixed-dose Regimen Daily Subcutaneous Anakinra for the Treatment of Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated:  10/12/2012
San Francisco General Hospital
mi
from
San Francisco, CA
Anakinra as a Treatment for Hydradenitis Suppurativa
An Open Label Non-randomized Study Assessing the Efficacy and Tolerability of Fixed-dose Regimen Daily Subcutaneous Anakinra for the Treatment of Moderate to Severe Hidradenitis Suppurativa
Status: Enrolling
Updated: 10/12/2012
San Francisco General Hospital
mi
from
San Francisco, CA
Click here to add this to my saved trials
Allogeneic Hematopoietic Stem Cell Transplantation (NST) for Patients With Systemic Sclerosis
Non-myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (NST) for Patients With Systemic Sclerosis
Status: Enrolling
Updated:  10/22/2012
Northwestern University Feinberg School of Medicine
mi
from
Chicago, IL
Allogeneic Hematopoietic Stem Cell Transplantation (NST) for Patients With Systemic Sclerosis
Non-myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (NST) for Patients With Systemic Sclerosis
Status: Enrolling
Updated: 10/22/2012
Northwestern University Feinberg School of Medicine
mi
from
Chicago, IL
Click here to add this to my saved trials
17% Salicylate Versus 17% Salicylate-Ethyl Pyruvate for Plantar Foot Warts
New Formulation of Salicylate to Improve Treatment of Common Skin Warts
Status: Enrolling
Updated:  10/22/2012
Main Line Foot and Ankle Center
mi
from
Ardmore, PA
17% Salicylate Versus 17% Salicylate-Ethyl Pyruvate for Plantar Foot Warts
New Formulation of Salicylate to Improve Treatment of Common Skin Warts
Status: Enrolling
Updated: 10/22/2012
Main Line Foot and Ankle Center
mi
from
Ardmore, PA
Click here to add this to my saved trials
Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis
A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Multicenter Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis of the Face or Balding Scalp
Status: Enrolling
Updated:  11/9/2012
Radiant Research, Inc.
mi
from
Tucson, AZ
Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis
A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Multicenter Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis of the Face or Balding Scalp
Status: Enrolling
Updated: 11/9/2012
Radiant Research, Inc.
mi
from
Tucson, AZ
Click here to add this to my saved trials
Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis
A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Multicenter Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis of the Face or Balding Scalp
Status: Enrolling
Updated:  11/9/2012
Encino Research Center
mi
from
Encino, CA
Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis
A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Multicenter Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis of the Face or Balding Scalp
Status: Enrolling
Updated: 11/9/2012
Encino Research Center
mi
from
Encino, CA
Click here to add this to my saved trials
Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis
A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Multicenter Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis of the Face or Balding Scalp
Status: Enrolling
Updated:  11/9/2012
Dermatology Research Associates
mi
from
Los Angeles, CA
Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis
A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Multicenter Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis of the Face or Balding Scalp
Status: Enrolling
Updated: 11/9/2012
Dermatology Research Associates
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis
A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Multicenter Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis of the Face or Balding Scalp
Status: Enrolling
Updated:  11/9/2012
Northern California Research
mi
from
Sacramento, CA
Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis
A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Multicenter Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis of the Face or Balding Scalp
Status: Enrolling
Updated: 11/9/2012
Northern California Research
mi
from
Sacramento, CA
Click here to add this to my saved trials
Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis
A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Multicenter Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis of the Face or Balding Scalp
Status: Enrolling
Updated:  11/9/2012
Skin Surgery Medical Group, Inc.
mi
from
San Diego, CA
Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis
A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Multicenter Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis of the Face or Balding Scalp
Status: Enrolling
Updated: 11/9/2012
Skin Surgery Medical Group, Inc.
mi
from
San Diego, CA
Click here to add this to my saved trials
Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis
A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Multicenter Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis of the Face or Balding Scalp
Status: Enrolling
Updated:  11/9/2012
Longmont Clinic, PC
mi
from
Longmont, CO
Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis
A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Multicenter Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis of the Face or Balding Scalp
Status: Enrolling
Updated: 11/9/2012
Longmont Clinic, PC
mi
from
Longmont, CO
Click here to add this to my saved trials
Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis
A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Multicenter Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis of the Face or Balding Scalp
Status: Enrolling
Updated:  11/9/2012
Visions Clinical Research
mi
from
Boynton Beach, FL
Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis
A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Multicenter Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis of the Face or Balding Scalp
Status: Enrolling
Updated: 11/9/2012
Visions Clinical Research
mi
from
Boynton Beach, FL
Click here to add this to my saved trials
Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis
A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Multicenter Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis of the Face or Balding Scalp
Status: Enrolling
Updated:  11/9/2012
Tampa Bay Medical Research Inc.
mi
from
Clearwater, FL
Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis
A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Multicenter Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis of the Face or Balding Scalp
Status: Enrolling
Updated: 11/9/2012
Tampa Bay Medical Research Inc.
mi
from
Clearwater, FL
Click here to add this to my saved trials
Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis
A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Multicenter Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis of the Face or Balding Scalp
Status: Enrolling
Updated:  11/9/2012
Jacksonville Center for Clinical Research
mi
from
Jacksonville, FL
Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis
A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Multicenter Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis of the Face or Balding Scalp
Status: Enrolling
Updated: 11/9/2012
Jacksonville Center for Clinical Research
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis
A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Multicenter Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis of the Face or Balding Scalp
Status: Enrolling
Updated:  11/9/2012
International Dermatology Research, Inc.
mi
from
Miami, FL
Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis
A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Multicenter Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis of the Face or Balding Scalp
Status: Enrolling
Updated: 11/9/2012
International Dermatology Research, Inc.
mi
from
Miami, FL
Click here to add this to my saved trials
Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis
A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Multicenter Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis of the Face or Balding Scalp
Status: Enrolling
Updated:  11/9/2012
Tory Sullivan, M.D., P.A.
mi
from
N. Miami Beach, FL
Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis
A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Multicenter Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis of the Face or Balding Scalp
Status: Enrolling
Updated: 11/9/2012
Tory Sullivan, M.D., P.A.
mi
from
N. Miami Beach, FL
Click here to add this to my saved trials
Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis
A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Multicenter Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis of the Face or Balding Scalp
Status: Enrolling
Updated:  11/9/2012
Park Avenue Dermatology
mi
from
Orange Park, FL
Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis
A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Multicenter Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis of the Face or Balding Scalp
Status: Enrolling
Updated: 11/9/2012
Park Avenue Dermatology
mi
from
Orange Park, FL
Click here to add this to my saved trials
Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis
A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Multicenter Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis of the Face or Balding Scalp
Status: Enrolling
Updated:  11/9/2012
Leavitt Medical Associates of Florida dba Ameriderm Research
mi
from
Ormond Beach, FL
Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis
A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Multicenter Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis of the Face or Balding Scalp
Status: Enrolling
Updated: 11/9/2012
Leavitt Medical Associates of Florida dba Ameriderm Research
mi
from
Ormond Beach, FL
Click here to add this to my saved trials
Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis
A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Multicenter Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis of the Face or Balding Scalp
Status: Enrolling
Updated:  11/9/2012
Radiant Research, Inc.
mi
from
Pinellas Park, FL
Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis
A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Multicenter Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis of the Face or Balding Scalp
Status: Enrolling
Updated: 11/9/2012
Radiant Research, Inc.
mi
from
Pinellas Park, FL
Click here to add this to my saved trials
Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis
A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Multicenter Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis of the Face or Balding Scalp
Status: Enrolling
Updated:  11/9/2012
MedaPhase, Inc.
mi
from
Newnan, GA
Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis
A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Multicenter Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis of the Face or Balding Scalp
Status: Enrolling
Updated: 11/9/2012
MedaPhase, Inc.
mi
from
Newnan, GA
Click here to add this to my saved trials
Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis
A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Multicenter Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis of the Face or Balding Scalp
Status: Enrolling
Updated:  11/9/2012
Altman Dermatology Associates
mi
from
Arlington Heights, IL
Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis
A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Multicenter Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis of the Face or Balding Scalp
Status: Enrolling
Updated: 11/9/2012
Altman Dermatology Associates
mi
from
Arlington Heights, IL
Click here to add this to my saved trials